BRIEF-Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease

* ABEONA THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN CLN1 DISEASE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.